These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17933420)

  • 1. Non-invasive diagnosis of pleural malignancies: the role of tumour markers.
    van den Heuvel MM; Korse CM; Bonfrer JM; Baas P
    Lung Cancer; 2008 Mar; 59(3):350-4. PubMed ID: 17933420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
    Amati M; Tomasetti M; Scartozzi M; Mariotti L; Ciuccarelli M; Valentino M; Governa M; Santarelli L
    G Ital Med Lav Ergon; 2007; 29(3 Suppl):335-8. PubMed ID: 18409713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
    Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
    Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
    Amati M; Tomasetti M; Scartozzi M; Mariotti L; Alleva R; Pignotti E; Borghi B; Valentino M; Governa M; Neuzil J; Santarelli L
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):163-70. PubMed ID: 18199721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
    Gaspar MJ; De Miguel J; García Díaz JD; Díez M
    Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
    Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
    PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
    Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
    Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
    Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
    Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble mesothelin-related protein--a blood test for mesothelioma.
    Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
    Lung Cancer; 2005 Jul; 49 Suppl 1():S109-11. PubMed ID: 15950789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
    Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.
    Filiberti R; Parodi S; Libener R; Ivaldi GP; Canessa PA; Ugolini D; Bobbio B; Marroni P
    Med Oncol; 2013 Jun; 30(2):543. PubMed ID: 23532816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for mesothelioma.
    Scherpereel A; Lee YC
    Curr Opin Pulm Med; 2007 Jul; 13(4):339-443. PubMed ID: 17534183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions.
    Bielsa S; Esquerda A; Salud A; Montes A; Arellano E; Rodríguez-Panadero F; Porcel JM
    Eur J Intern Med; 2009 Jul; 20(4):383-6. PubMed ID: 19524179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.
    Cristaudo A; Foddis R; Vivaldi A; Guglielmi G; Dipalma N; Filiberti R; Neri M; Ceppi M; Paganuzzi M; Ivaldi GP; Mencoboni M; Canessa PA; Ambrosino N; Chella A; Mutti L; Puntoni R
    Clin Cancer Res; 2007 Sep; 13(17):5076-81. PubMed ID: 17785560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.